Association Between Baseline Hypertension and Longitudinal Functional Status in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten
Year: 2026
Type: article
Study design: Observational Study
Abstract: Hypertension is common in hypertrophic cardiomyopathy (HCM) yet its impact on patients on long-term mavacamten is unknown. In this single-center observational study of 163 patients with symptomatic obstructive HCM treated with mavacamten for up to 108 weeks, hemodynamic and functional responses stratified by baseline hypertension status (60.7% hypertensive) were compared. Mavacamten produced similar reductions in resting and Valsalva LVOT gradients regardless of hypertension status. However, patients with hypertension had a significantly lower probability of achieving NYHA Class I functional status over time (interaction p=0.01). These findings suggest that hypertension-related factors beyond LVOT obstruction may limit complete functional recovery in obstructive HCM despite effective gradient reduction with mavacamten.
Source: Journal of Cardiac Failure
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,970
Funders: Bristol-Myers Squibb, AstraZeneca, Cytokinetics, Novo Nordisk, Idorsia Pharmaceuticals, Grifols, National Institutes of Health, American Regent, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, NHLBI Division of Intramural Research
OpenAlex ID: W7127044730